Is Rein Therapeutics, Inc. (RNTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 40.8% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 40.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 20.7% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | 0.0% / 33% | 40.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 20.7% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -83.3% | |
| Return on Assets (ROA) | -18.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$22M |
| Free Cash Flow | -$22M |
| Total Debt | $0 |
| Current Ratio | 0.9 |
| Total Assets | $62M |
Price & Trading
| Last Close | $1.27 |
| 50-Day MA | $1.25 |
| 200-Day MA | $1.32 |
| Avg Volume | 127K |
| Beta | 1.5 |
|
52-Week Range
$1.02
| |
About Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Rein Therapeutics, Inc. (RNTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Rein Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Rein Therapeutics, Inc.'s debt ratio?
Rein Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Rein Therapeutics, Inc.'s key financial metrics?
Rein Therapeutics, Inc. has a market capitalization of $35M. Return on equity stands at -83.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.